E64FC26 is a potent pan-inhibitor of the protein disulfide isomerase (PDI) family, with IC 50 s of 1.9, 20.9, 25.9, 16.3, and 25.4 μM against PDIA1, PDIA3, PDIA4, TXNDC5, and PDIA6, respectively. E64FC26 shows anti-myeloma activity. In Vitro E64FC26 (0.01-100 μM; 24 hours) shows anti-MM activity , with an EC 50 of 0.59 μM.?\nE64FC26 is more cytotoxic against a genetically diverse panel of multiple myeloma (MM) cell lines (KMS11, OPM2, MM.1S BzR, MM.1S, SA-13, U266 BzR, ANBL6, KMS12PE, U266, 8226 DxR, 8226 BzR, KMS12BM, H929,8226 cells) when compared to non-malignant cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: MM.1S BzR cells Concentration: 0.01, 0.1, 1, 10, 100 µM Incubation Time: 24 hours Result: Showed anti-MM activity , with an EC 50 of 0.59 μM. In Vivo E64FC26 (2 mg/ kg; i.p.; three days a week for 7days) shows anti-MM effect in NSG mice model, and increases median survival by 2 weeks . ?\nThe combination of E64FC26 and Bortezomib produced the greatest improvement in survival, extending the median survival by 20 days . ?\nPharmacokinetic of E64FC26 was measured in CD-1 mice. E64FC26 was administered i.v. (2 mg/kg; gray tracing) or p.o. (5 mg/ kg; blue tracing) and plasma drug concentrations were measured over a 24 h period. In CD-1 mice demonstrated adequate oral bioavailabilty of 34% with systemic exposure approaching a maximum concentration (C max ) of 400 nM after a single oral dose of 5 mg/kg with a terminal half-life of 9.5 h . ?\nVk*MYC transgenic mice are treated with E64FC26 (2 mg/kg, i.p., 3 days/week) for two consecutive weeks. E64FC26 treatment induces an immediate anti-MM response, decreasing serum M-protein in all mice by an average of 33 ± 7.9% . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: NOD-SCID IL2Rγ-/- (NSG) mice (bearing MM.1S cells) Dosage: 2 mg/ kg Administration: i.p.; three days a week for 7days Result: Showed a clear anti-MM effect in this model also, increasing median survival by 2 weeks. Form:Solid